Neuron
Volume 80, Issue 1, 2 October 2013, Pages 80-96
Journal home page for Neuron

Article
Neuroprotection through Excitability and mTOR Required in ALS Motoneurons to Delay Disease and Extend Survival

https://doi.org/10.1016/j.neuron.2013.07.027Get rights and content
Under an Elsevier user license
open archive

Highlights

  • A growing excitability signaling deficit in motoneurons drives disease in ALS mice

  • Enhancing motoneuron excitability provides neuroprotection to FALS motoneurons

  • Metabotropic cholinergic signaling provides neuroprotection through mTOR

  • Enhancing mTOR activation while reducing ER stress delays disease progression

Summary

Delaying clinical disease onset would greatly reduce neurodegenerative disease burden, but the mechanisms influencing early preclinical progression are poorly understood. Here, we show that in mouse models of familial motoneuron (MN) disease, SOD1 mutants specifically render vulnerable MNs dependent on endogenous neuroprotection signaling involving excitability and mammalian target of rapamycin (mTOR). The most vulnerable low-excitability FF MNs already exhibited evidence of pathology and endogenous neuroprotection recruitment early postnatally. Enhancing MN excitability promoted MN neuroprotection and reversed misfolded SOD1 (misfSOD1) accumulation and MN pathology, whereas reducing MN excitability augmented misfSOD1 accumulation and accelerated disease. Inhibiting metabotropic cholinergic signaling onto MNs reduced ER stress, but enhanced misfSOD1 accumulation and prevented mTOR activation in alpha-MNs. Modulating excitability and/or alpha-MN mTOR activity had comparable effects on the progression rates of motor dysfunction, denervation, and death. Therefore, excitability and mTOR are key endogenous neuroprotection mechanisms in motoneurons to counteract clinically important disease progression in ALS.

Cited by (0)

6

These authors contributed equally to this work